Table 4.
Open in new tab

Discontinuation: all causes.

Methotrexate discontinued [n = 67]Tioguanine discontinued [n = 41]
Treatment duration—weeks, median [IQR]27.0 [8.0-51.0]29.0 [13.5-60.5]
Discontinuation reason, N [%]
 Adverse event46 [68.7]19 [46.3]
 Remission3 [4.5]2 [4.9]
 Primary non-response6 [9.0]8 [19.5]
 Loss of response5 [7.5]7 [17.1]
 Pregnancy3 [4.5]0 [0.0]
 Patient request2 [3.0]3 [7.3]
 Comorbidities2 [3.0]2 [4.9]
Methotrexate discontinued [n = 67]Tioguanine discontinued [n = 41]
Treatment duration—weeks, median [IQR]27.0 [8.0-51.0]29.0 [13.5-60.5]
Discontinuation reason, N [%]
 Adverse event46 [68.7]19 [46.3]
 Remission3 [4.5]2 [4.9]
 Primary non-response6 [9.0]8 [19.5]
 Loss of response5 [7.5]7 [17.1]
 Pregnancy3 [4.5]0 [0.0]
 Patient request2 [3.0]3 [7.3]
 Comorbidities2 [3.0]2 [4.9]

IQR, interquartile range.

Table 4.
Open in new tab

Discontinuation: all causes.

Methotrexate discontinued [n = 67]Tioguanine discontinued [n = 41]
Treatment duration—weeks, median [IQR]27.0 [8.0-51.0]29.0 [13.5-60.5]
Discontinuation reason, N [%]
 Adverse event46 [68.7]19 [46.3]
 Remission3 [4.5]2 [4.9]
 Primary non-response6 [9.0]8 [19.5]
 Loss of response5 [7.5]7 [17.1]
 Pregnancy3 [4.5]0 [0.0]
 Patient request2 [3.0]3 [7.3]
 Comorbidities2 [3.0]2 [4.9]
Methotrexate discontinued [n = 67]Tioguanine discontinued [n = 41]
Treatment duration—weeks, median [IQR]27.0 [8.0-51.0]29.0 [13.5-60.5]
Discontinuation reason, N [%]
 Adverse event46 [68.7]19 [46.3]
 Remission3 [4.5]2 [4.9]
 Primary non-response6 [9.0]8 [19.5]
 Loss of response5 [7.5]7 [17.1]
 Pregnancy3 [4.5]0 [0.0]
 Patient request2 [3.0]3 [7.3]
 Comorbidities2 [3.0]2 [4.9]

IQR, interquartile range.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close